Jake Rubens News Today

Launching a company based on knowledge that “the fundamental principle that most people hold to be true is off by a trillion” is a rare opportunity, said Jake Rubens, co-founder and president of Quotient Therapeutics Inc., a company that emerged from stealth this week, backed by two years of platform development and a $50 million investment from Flagship Pioneering.

Launching a company based on knowledge that “the fundamental principle that most people hold to be true is off by a trillion” is a rare opportunity, said Jake Rubens, co-founder and president of Quotient Therapeutics Inc., a company that emerged from stealth this week, backed by two years of platform development and a $50 million investment from Flagship Pioneering.

CRISPR-Cas9 systems are attaining greater power and precision, and alternatives such as homing nuclease and “gene writer” systems are becoming more capable, too.

Insider scoured startups, venture creation firms and accelerators to find the young founders creating scores of biotechs.